{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:37Z","timestamp":1791207337551,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/leu.2017.175","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T06:40:41Z","timestamp":1496904041000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL"],"prefix":"10.1038","volume":"32","author":[{"given":"J R","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Barrientos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N M","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S P","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R R","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cymbalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Caligaris-Cappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-4376","authenticated-orcid":false,"given":"J","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Montillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"DeVos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D F","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"BFleu2017175_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230\u2013239.","journal-title":"Lancet"},{"key":"BFleu2017175_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","volume":"25","author":"IW Flinn","year":"2007","unstructured":"Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793\u2013798.","journal-title":"J Clin Oncol"},{"key":"BFleu2017175_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164\u20131174.","journal-title":"Lancet"},{"key":"BFleu2017175_CR4","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079\u20134088.","journal-title":"J Clin Oncol"},{"key":"BFleu2017175_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303\u2013309.","journal-title":"Blood"},{"key":"BFleu2017175_CR6","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2010-04-281253","volume":"116","author":"T Zenz","year":"2010","unstructured":"Zenz T, Busch R, Fink A, Winkler D, Fischer K, B\u00fchler A et al. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: Results from the CLL8 trial of the GCLLSG. Blood 2010; 116: 2427.","journal-title":"Blood"},{"key":"BFleu2017175_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-06-583765","volume":"124","author":"CS Tam","year":"2014","unstructured":"Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 2014; 124: 3059\u20133064.","journal-title":"Blood"},{"key":"BFleu2017175_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1128\/CMR.00001-09","volume":"22","author":"AJ Fried","year":"2009","unstructured":"Fried AJ, Bonilla FA . Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009; 22: 396\u2013414.","journal-title":"Clin Microbiol Rev"},{"key":"BFleu2017175_CR9","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075\u201313080.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017175_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFleu2017175_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O'Brien","year":"2016","unstructured":"O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17: 1409\u20131418.","journal-title":"Lancet Oncol"},{"key":"BFleu2017175_CR12","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1200\/JCO.2011.34.7872","volume":"29","author":"M Trbusek","year":"2011","unstructured":"Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 2703\u20132708.","journal-title":"J Clin Oncol"},{"key":"BFleu2017175_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ord\u00f3\u00f1ez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101\u2013105.","journal-title":"Nature"},{"key":"BFleu2017175_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.1032","volume":"44","author":"V Quesada","year":"2011","unstructured":"Quesada V, Conde L, Villamor N, Ord\u00f3\u00f1ez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44: 47\u201352.","journal-title":"Nat Genet"},{"key":"BFleu2017175_CR15","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","volume":"365","author":"L Wang","year":"2011","unstructured":"Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497\u20132506.","journal-title":"N Engl J Med"},{"key":"BFleu2017175_CR16","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854\u20132862.","journal-title":"Blood"},{"key":"BFleu2017175_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3324\/haematol.2012.069369","volume":"98","author":"R Fo\u00e0","year":"2013","unstructured":"Fo\u00e0 R, Del Giudice I, Guarini A, Rossi D, Gaidano G . Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013; 98: 675\u2013685.","journal-title":"Haematologica"},{"key":"BFleu2017175_CR18","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, D\u00f6hner K et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123: 3247\u20133254.","journal-title":"Blood"},{"key":"BFleu2017175_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.527.527","volume":"122","author":"E Tausch","year":"2013","unstructured":"Tausch E, Beck P, Schlenk R, Kless S, Galler C, Hillmen P et al. NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): Results from the phase III study complement 1 (OMB110911). Blood 2013; 122: 257.","journal-title":"Blood"},{"key":"BFleu2017175_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521\u2013529.","journal-title":"Blood"},{"key":"BFleu2017175_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Be\u00e0 S et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100\u20131106.","journal-title":"Leukemia"},{"key":"BFleu2017175_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023\u20131031.","journal-title":"Nat Biotechnol"},{"key":"BFleu2017175_CR23","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","volume":"118","author":"D Rossi","year":"2011","unstructured":"Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904\u20136908.","journal-title":"Blood"},{"key":"BFleu2017175_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","volume":"23","author":"L Yu","year":"2017","unstructured":"Yu L, Kim HT, Kasar SN, Benien P, Du W, Hoang K et al. Survival of del17p CLL depends on genomic complexity and somatic mutation. Clin Cancer Res 2017; 23: 735\u2013745.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017175_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014; 123: 1810\u20131817.","journal-title":"Blood"},{"key":"BFleu2017175_CR26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/leu.2014.122","volume":"28","author":"SE Herman","year":"2014","unstructured":"Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188\u20132196.","journal-title":"Leukemia"},{"key":"BFleu2017175_CR27","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497\u20132506.","journal-title":"Blood"},{"key":"BFleu2017175_CR28","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425\u20132437.","journal-title":"N Engl J Med"},{"key":"BFleu2017175_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 2015; 1: 80\u201387.","journal-title":"JAMA Oncol"},{"key":"BFleu2017175_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/leu.2016.316","volume":"31","author":"L Kazianka","year":"2016","unstructured":"Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2016; 31: 1117\u20131122.","journal-title":"Leukemia"},{"key":"BFleu2017175_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783\u2013787.","journal-title":"Leukemia"},{"key":"BFleu2017175_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, L\u00e9vy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 2016; 175: 462\u2013466.","journal-title":"Br J Haematol"},{"key":"BFleu2017175_CR33","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062\u20132067.","journal-title":"Blood"},{"key":"BFleu2017175_CR34","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","volume":"101","author":"M Winqvist","year":"2016","unstructured":"Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica 2016; 101: 1573\u20131580.","journal-title":"Haematologica"},{"key":"BFleu2017175_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S et al. HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17: 200\u2013211.","journal-title":"Lancet Oncol"},{"key":"BFleu2017175_CR36","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","volume":"123","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kay NE, Shanafelt TD . How we treat Richter syndrome. Blood 2014; 123: 1647\u20131657.","journal-title":"Blood"},{"key":"BFleu2017175_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208\u2013215.","journal-title":"Blood"},{"key":"BFleu2017175_CR38","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","volume":"56","author":"O Benjamini","year":"2015","unstructured":"Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2015; 56: 1643\u20131650.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017175_CR39","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","volume":"123","author":"D Rossi","year":"2014","unstructured":"Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139\u20132147.","journal-title":"Blood"},{"key":"BFleu2017175_CR40","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, Denzel T, H\u00e4be S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473\u20134479.","journal-title":"J Clin Oncol"},{"key":"BFleu2017175_CR41","unstructured":"Jones J, Coutre S, Byrd JC, Furman R, Hillmen P, Mato A et al Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes. Presented at: 21st Congress of the European Hematology Association; June 9-12, 2016; Copenhagen, Denmark, Abstract S429."},{"key":"BFleu2017175_CR42","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015; 121: 3612\u20133621.","journal-title":"Cancer"},{"key":"BFleu2017175_CR43","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 2016; 127: 2122\u20132130.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017175","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:07:49Z","timestamp":1684433269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFleu2017175"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.175","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JRB has received honoraria from Celgene, Gilead, Infinity, Genentech\/Roche, Janssen, Pharmacyclics, Pfizer and Sub BioPharma, has served in an advisory role for Celgene, Gilead, Infinity, Genentech, Janssen, Pfizer and Pharmacyclics, and has been reimbursed for expenses by Gilead, Sun BioPharma, Pfizer and Janssen. PH has served as a consultant for Roche, Glaxo Smith Kline, Janssen, Gilead, and AbbVie, received honoraria from AbbVie, Gilead, Glaxo Smith Kline, Roche, Novartis, Pharmacyclics and Janssen, and research funding from Roche, Novartis, Glaxo Smith Kline, Janssen, Gilead, AbbVie, Celgene, Pharmacyclics. SOB has served as a consultant and received honoraria from Pharmacyclics and Janssen, and received research funding from Pharmacyclics. JCBarrientos has served as a consultant to Gilead, AbbVie, and Janssen, and received research funding from AbbVie and Gilead. NMR has served as a consultant for Celgene, Infinity, Gilead, and AbbVie. SEC has served in an advisory role for Janssen and Pharmacyclics, and has received research funding from AbbVie and Pharmacyclics. CT has received honoraria from Janssen, research funding from Janssen, and has served in an advisory role for Janssen. SPM has served as a consultant for and received honoraria from AbbVie, Gilead, Glaxo Smith Kline, Janssen, Roche, received research funding from AbbVie, Janssen, Roche, participated in speakers\u2019 bureau for AbbVie, Gilead, Janssen, Roche. UJ has served as a consultant, and received honoraria and reimbursements from Janssen and Roche. PMB has served as a consultant for Pharmacyclics, AbbVie and received research funding from Pharmacyclics. RRF has received honoraria from Pharmacyclics, and has served in an advisory role and on Speakers\u2019 Bureaus for Pharmacyclics. TJK has served as a consultant for AbbVie, Genentech, Gilead, and received research funding from AbbVie, Genentech, Pharmacyclics. FC has received research funding from Janssen, honoraria from Gilead, Janssen, Mundipharma and AbbVie, has consulted for Gilead, Janssen and AbbVie, and been reimbursed by Janssen, and Roche. PT has served as a consultant for Janssen. FCC has received honoraria and served as a consultant for Celgene, Janssen, Pharmacyclics. JD has received honoraria from and served as a consultant for Gilead, Novartis, Glaxo Smith Kline, Janssen, Roche, and received research funding from Infinity, Roche. MM has received honoraria from and served in a consultancy role for Roche, Gilead, and Janssen, and received honoraria from Novartis. SDV and CM have no relevant conflicts of interest to disclose. JMP has served as a consultant for Gilead and Pharmacyclics, and received research funding from Pharmacyclics, AbbVie, and TG Therapeutics. TM has received honoraria from Pharmacyclics, Gilead, and Alexion and has served as a consultant for Morphosys. JAB has served as a consultant for Janssen, Portola, has received research funding from Gilead, Pharmacyclics, and reimbursement from Janssen, Roche. DC is employed by Pharmacyclics and has stock\/ownership in Gilead and AbbVie. JL, LG, BC, GC, EH, DFJ are employed by Pharmacyclics and have stock\/ownership in AbbVie. JCByrd has no relevant conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}